Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
Authors
Keywords
Metastatic renal cell carcinoma, Sunitinib, Biomarkers, Phase III clinical trial
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 73, Issue 1, Pages 151-161
Publisher
Springer Nature
Online
2013-11-12
DOI
10.1007/s00280-013-2333-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
- (2013) M Scartozzi et al. BRITISH JOURNAL OF CANCER
- Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
- (2013) B Beuselinck et al. BRITISH JOURNAL OF CANCER
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
- (2010) N. R. Smith et al. CLINICAL CANCER RESEARCH
- Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2010) C. Pena et al. CLINICAL CANCER RESEARCH
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
- (2010) Camillo Porta et al. KIDNEY INTERNATIONAL
- Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon- : association of pretreatment serum levels with survival
- (2009) A. J. Montero et al. ANNALS OF ONCOLOGY
- A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity
- (2009) Marcella M. Baldewijns et al. BJU INTERNATIONAL
- A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer
- (2009) Daniel Y. C. Heng et al. CANCER
- Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications
- (2009) Marcin Wysoczynski et al. INTERNATIONAL JOURNAL OF CANCER
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia inducible factor-1α correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma
- (2009) Gordana Đorđević et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The Interleukin-8 Pathway in Cancer
- (2008) D. J.J. Waugh et al. CLINICAL CANCER RESEARCH
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
- (2008) Tuomas Tammela et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search